Novo Nordisk (NVO) Stock Forecast & Price Target

Compare

9,330 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NVO Analyst Ratings

Hold

3 Buy

5 Hold

1 Sell

Based on 9 analysts giving stock ratings to

Novo

Nordisk

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NVO Stock 12 Month Forecast

Average Price Target

$92.15

▲(40.11% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Novo Nordisk in the last 3 months. The average price target is $92.15 with a high forecast of $136.93 and a low forecast of $61.00. The average price target represents a 40.11% change from the last price of $65.77.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"60":"$60","81":"$81","102":"$102","123":"$123","144":"$144"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":136.93,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$136.93</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":92.15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$92.15</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":61,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$61.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[60,81,102,123,144],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,65.6,71.08692307692307,76.57384615384615,82.06076923076922,87.5476923076923,93.03461538461538,98.52153846153846,104.00846153846155,109.49538461538461,114.9823076923077,120.46923076923076,125.95615384615385,131.44307692307694,{"y":136.93,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,65.6,67.64230769230768,69.68461538461538,71.72692307692307,73.76923076923077,75.81153846153846,77.85384615384615,79.89615384615385,81.93846153846154,83.98076923076923,86.02307692307693,88.06538461538462,90.1076923076923,{"y":92.15,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,65.6,65.24615384615385,64.89230769230768,64.53846153846153,64.18461538461538,63.83076923076923,63.47692307692307,63.12307692307692,62.76923076923077,62.41538461538461,62.06153846153846,61.707692307692305,61.353846153846156,{"y":61,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":127.4,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":133.39,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":143.39,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.61,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137.58,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":116.67,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.67,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.44,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.04,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.49,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.62,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.03,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.6,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$136.93

Average Price Target$92.15

Lowest Price Target$61.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Michael Nedelcovych

TD Cowen

―

Buy

―

Reiterated

05/07/25

Evan Seigerman

BMO Capital

$64

Hold

-2.69%

Downside

Reiterated

04/29/25

Rajesh Kumar

HSBC

$160→$102

Buy

55.09%

Upside

Reiterated

04/28/25

Seamus Fernandez

Guggenheim

―

Hold

―

Downgraded

04/17/25

Peter Verdult

Exane BNP Paribas

$61

Sell

-7.25%

Downside

Initiated

04/15/25

Sachin Jain

Bank of America Securities

$136.93

Buy

108.19%

Upside

Reiterated

03/28/25

Thibault Boutherin

Morgan Stanley

$99

Hold

50.52%

Upside

Reiterated

03/27/25

Unknown Analyst

Not Ranked

Berenberg Bank

$100→$90

Hold

36.84%

Upside

Reiterated

03/24/25

Unknown Analyst

Not Ranked

Stifel Nicolaus

―

Hold

―

Downgraded

03/03/25

Wan Nurhayati

CFRA

$122→$90

Hold

36.84%

Upside

Reiterated

01/21/25

Jasper Hellweg

Argus Research

―

Buy

―

Reiterated

01/16/25

James Quigley

Goldman Sachs

$148→$124

Buy

88.54%

Upside

Reiterated

01/13/25

Unknown Analyst

Not Ranked

Bernstein

―

Hold

―

Upgraded

01/06/25

Peter Welford

Jefferies

$81.5

Sell

23.92%

Upside

Reiterated

12/20/24

Hans Engel

Erste Group

―

Hold

―

Downgraded

10/28/24

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Michael Nedelcovych

TD Cowen

―

Buy

―

Reiterated

05/07/25

Evan Seigerman

BMO Capital

$64

Hold

-2.69%

Downside

Reiterated

04/29/25

Rajesh Kumar

HSBC

$160→$102

Buy

55.09%

Upside

Reiterated

04/28/25

Seamus Fernandez

Guggenheim

―

Hold

―

Downgraded

04/17/25

Peter Verdult

Exane BNP Paribas

$61

Sell

-7.25%

Downside

Initiated

04/15/25

Sachin Jain

Bank of America Securities

$136.93

Buy

108.19%

Upside

Reiterated

03/28/25

Thibault Boutherin

Morgan Stanley

$99

Hold

50.52%

Upside

Reiterated

03/27/25

Unknown Analyst

Not Ranked

Berenberg Bank

$100→$90

Hold

36.84%

Upside

Reiterated

03/24/25

Unknown Analyst

Not Ranked

Stifel Nicolaus

―

Hold

―

Downgraded

03/03/25

Wan Nurhayati

CFRA

$122→$90

Hold

36.84%

Upside

Reiterated

01/21/25

Jasper Hellweg

Argus Research

―

Buy

―

Reiterated

01/16/25

James Quigley

Goldman Sachs

$148→$124

Buy

88.54%

Upside

Reiterated

01/13/25

Unknown Analyst

Not Ranked

Bernstein

―

Hold

―

Upgraded

01/06/25

Peter Welford

Jefferies

$81.5

Sell

23.92%

Upside

Reiterated

12/20/24

Hans Engel

Erste Group

―

Hold

―

Downgraded

10/28/24

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Novo Nordisk

Which Analyst Should I Follow If I Want to Buy NVO and Sell After:

1 Month

xxx

Success Rate

13/24 ratings generated profit

Average Return

+0.29%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 54.17% of your transactions generating a profit, with an average return of +0.29% per trade.

3 Months

xxx

Success Rate

12/24 ratings generated profit

Average Return

+0.10%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +0.10% per trade.

1 Year

Sachin JainBank of America Securities

Success Rate

8/24 ratings generated profit

Average Return

-3.79%

reiterated a buy rating 2 months ago

Copying Sachin Jain's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -3.79% per trade.

2 Years

xxx

Success Rate

3/15 ratings generated profit

Average Return

-14.51%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 20.00% of your transactions generating a profit, with an average return of -14.51% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NVO Analyst Recommendation Trends

Rating

Jan 25

Feb 25

Mar 25

Apr 25

May 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NVO has received 8 Buy Ratings, 8 Hold Ratings, and 1 Sell Ratings. NVO average Analyst price target in the past 3 months is 92.15.

Each month's total comprises the sum of three months' worth of ratings.

NVO Financial Forecast

NVO Earnings Forecast

Next quarter’s earnings estimate for NVO is $0.91 with a range of $0.82 to $0.96. The previous quarter’s EPS was $0.99. NVO beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 39.90% of the time in the same period. In the last calendar year NVO has Outperformed its overall industry.

NVO Sales Forecast

Next quarter’s sales forecast for NVO is $11.84B with a range of $11.22B to $12.42B. The previous quarter’s sales results were ―. NVO beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 41.07% of the time in the same period. In the last calendar year NVO has Outperformed its overall industry.

NVO Stock Forecast FAQ

What is NVO’s average 12-month price target, according to analysts?

Based on analyst ratings, Novo Nordisk’s 12-month average price target is 92.15.

What is NVO’s upside potential, based on the analysts’ average price target?

Novo Nordisk has 40.11% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NVO a Buy, Sell or Hold?

Novo Nordisk has a consensus rating of Hold which is based on 3 buy ratings, 5 hold ratings and 1 sell ratings.

What is Novo Nordisk’s price target?

The average price target for Novo Nordisk is 92.15. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $136.93 ,the lowest forecast is $61.00. The average price target represents 40.11% Increase from the current price of $65.77.

What do analysts say about Novo Nordisk?

Novo Nordisk’s analyst rating consensus is a Hold. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of NVO?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Novo Nordisk (NVO) Stock Forecast & Price Target

NVO Analyst Ratings

NVO Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Novo Nordisk

NVO Analyst Recommendation Trends

NVO Financial Forecast

NVO Earnings Forecast

NVO Sales Forecast

NVO Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts